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A functional variant of the myeloperoxidase gene is associated cated as one important cause of the sustained inflamma-
with cardiovascular disease in end-stage renal disease patients. tory activity [1]. Owing to the putative pro-atherogenic
Cardiovascular disease (CVD) is the leading cause of mortal-
effects of intravascular inflammation, we hypothesize thatity in end-stage renal disease (ESRD) patients and there is
factors regulating the inflammatory and oxidative stressemerging evidence that genetic factors may contribute to the
development of atherosclerosis. Myeloperoxidase (MPO) is an response may contribute to the high prevalence of car-
abundant enzyme involved in the production of free radicals. diovascular disease in ESRD.
A functional G→A single nucleotide polymorphism (SNP) has
Myeloperoxidase (MPO) is a hemoprotein foundbeen identified at position 463, where the A allele is associ-
mainly in neutrophils, but to a lower extent also in mono-ated with lower MPO expression. To analyze the association be-
tween this SNP and inflammation, oxidative stress, and CVD, cytes. The main biological function of MPO is the de-
we studied a cohort of 155 ESRD patients (52  1 years, 62% fense of the organism, catalyzing the production of hypo-males, 22% diabetics) shortly before the initiation of dialysis
chlorous acid, and enhancing antimicrobial activity. Aparttreatment. CVD was defined by medical history criteria; plasma
interleukin-6 (IL-6) was used as a marker of inflammation, from its diagnostic relevance in acute myeloid leukemia,
and plasma pentosidine as an estimation of oxidative protein MPO has recently attracted significant attention, since
damage. DNA from leukocytes was used for genotyping, per- it seems to be also involved in a broad range of noninfec-formed by the pyrosequencing reaction. Only five patients
tious diseases, such as lung cancer, Alzheimer’s disease,(3%) had the genotype AA at the 463 position, whereas 38
(25%) had the GA and 112 (72%) had the GG genotype. multiple sclerosis, atherosclerosis, and vasculitis [2]. It
No differences were noted in plasma IL-6 levels between the could be hypothesized that MPO may be linked to these
genotype groups, whereas the pentosidine levels were higher
pathologic states through its strong oxidative activityin the GG group (28.4 pmol/mg albumin [range, 8.5 to 123
and/or its genetic variations characterized by differentialpmol/mg albumin]) compared to the other two groups (21.4
pmol/mg albumin [range, 7.6 to 384 pmol/mg albumin; P  expression of the protein. Recently, an important func-
0.05]). Patients with the GG genotype had a higher prevalence tional single nucleotide polymorphism (SNP) has been
of positive serology for Chlamydia pneumoniae (51%) when
identified in the promoter region of the MPO gene, con-compared to the carriers of the A allele (24%) (P  0.05).
sisting of a G to A substitution (463G→A). PreviousThe prevalence of CVD was lower in the AA (0%) and GA
genotypes (18%), compared to the GG genotype (35%). The studies have demonstrated that the G allele (in contrast
GG genotype was still associated with CVD after correction to A allele) creates a strong SP1 binding site, which isfor age, diabetes, smoking, malnutrition, and inflammation.
correlated with a 25-fold transcriptional enhancement ofOur findings suggest that the 463 G→A SNP, which suppos-
edly results in lower MPO activity, is associated with a lower the gene [3].
prevalence of CVD in ESRD patients. It could be speculated The description of a highly functional genetic variation
that this effect is mediated by a decreased oxidative stress due in the MPO gene offers an opportunity for an evaluationto lower production of free radicals.
of the hypothesis that the oxidative stress response plays
a role in the development of atherosclerotic cardiovas-
cular disease in ESRD patients. For this purpose, weEnd-stage renal disease (ESRD) is considered a pro-
assessed the associations between the 463G→A MPOinflammatory state, and oxidative stress has been impli-
SNP and plasma pentosidine, inflammation, chronic
infection (C. pneumoniae), and cardiovascular diseaseKey words: end-stage renal disease, oxidative stress, myeloperoxidase,
genetic polymorphism. (CVD) in a group of incident ESRD patients starting
dialysis treatment. 2003 by the International Society of Nephrology
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METHODS ment from Pyrosequencing AB (Uppsala, Sweden), as
described elsewhere [4]. The sequencing primer usedStudy subjects
was 5-CCTGACCTCAAGTGATCCACC-3.
This study is part of an ongoing prospective study
designed to evaluate risk factors for the development of Statistical analysis
complications in ESRD patients. One hundred and fifty Comparisons between groups of patients were per-
five ESRD patients were recruited shortly before the formed using the Student t test or Mann Whitney test
initiation of renal replacement therapy. The glomerular when appropriate, whereas comparisons between two
filtration rate (GFR) was estimated by the mean of urea groups for nominal variables were made with chi-square
and creatinine clearances. Information on CVD (coro- or Fisher’s exact test. Due to the low prevalence of the
nary artery disease, cerebrovascular disease, and periph- AA genotype, these patients were grouped with the GA
eral artery disease) was obtained from a detailed medical genotype for statistical analysis. The association between
history. Malnutrition was defined as a subjective global the genotypes and CVD was examined using chi-square
assessment (SGA) 2. test, and confirmed with logistic regression following a
two-step approach. In the first step, we analyzed, in anLaboratory methods
univariate fashion, the following risk factors: age, male
The plasma levels of the IL-6 and pentosidine were gender, diabetes, smoking, total cholesterol, pulse pres-
determined in plasma EDTA samples stored at 70C. sure, and systolic and diastolic blood pressure (traditional
Plasma IL-6 was measured using ultrasensitive ELISA risk factors), as well as the nontraditional risk factors
kits (Boerhinger Mannheim, Mannheim, Germany). Pen- inflammation (plasma IL-6) and malnutrition (SGA2).
tosidine was measured using reverse phase high-pressure All parameters that were significantly associated with
liquid chromatography (HPLC) and adjusted for serum CVD in the univariate model (MPO GG genotype, age,
albumin concentration (expressed as pmol/mg albumin). diabetes, smoking, IL-6, and malnutrition) were then en-
S-albumin was determined using the bromocresol method. tered into a second logistic regression model. Values are
C. pneumoniae, IgG, and IgA antibodies obtained from presented as mean  SEM or medians with P  0.05
Thermo Labsystems (Helsinki, Finland) were measured indicating significance. All the results were analyzed us-
by the microimmunofluoresence method with elemen- ing StatView for Windows (SAS, Inc., Cary, NC, USA).
tary bodies of C. pneumoniae strain IOL 207 used as a
representative C. pneumoniae strain type. IgG and IgA
RESULTStiters of 1/64 or greater were considered positive.
The study population consisted of 155 patients (62%
Genotyping methods males) with a mean age of 52  2 years. The primary
renal disease was diabetic nephropathy in 35 patientsAt recruitment, a 5 mL EDTA sample of peripheral
blood was drawn, from which DNA was extracted using (23%), chronic glomerulonephritis in 40 patients (26%),
polycystic kidney disease in 16 patients (10%), and other,QIAamp DNA kit (Qiagen Inc., Valencia, Lousiana).
Samples were stored at20C. The design of the sequenc- or unknown causes in 64 patients (41%). Cardiovascular
atherosclerotic disease, as defined by medical history,ing primers was performed using the software Primer
Designer 4 for Windows, version 4.1, (scientific and was present in 46 patients (30%). The median IL-6 con-
centration was 6.1 pg/mL (range, 0.9 to 44.9 pg/mL).educational software, Durham, NC) and all oligonucleo-
tides were synthesized by Interactiva (Ulm, Germany). Of the 155 ESRD patients tested, 112 (72%) were
homozygous for the GG genotype, 5 (3%) for the AA ge-Sequence amplification was performed using the poly-
merase chain reaction (PCR) on a PTC-225 Thermocy- notype, and 38 (25%) were heterozygous. As expected,
our results do not deviate from Hardy-Weinberg Equi-cler (MJ Research, Inc., Cambridge, MA, USA). The
PCR reaction volume was 50 L, containing 20 to 50 ng librium (chi-square 0.62, PNS). The main characteris-
tics of the patients, according to the genotype, are de-of DNA, 10 pmol of forward and reverse primers, 0.2 mM
of each dNTP, 0.3 U of DyNAzyme II (DNA Polymer- scribed in Table 1. There were no differences between
the groups regarding age, gender, nor residual renal func-ase; Finnzymes, California, USA), 10 mM of Tris-HCl,
1.5 mM of MgCl2, 50 mM of KCl, and 0.1% Triton X-100. tion, IL-6 levels, and the prevalence of diabetes mellitus.
In contrast, the concentration of plasma pentosidine wasThe primers used for the PCR reaction were 5-CGGT
ATAGGCACACAATGGTGAG-3 (forward primer) higher in the GG genotype (28.4 pmol/mg albumin
[range, 8.5 to 123 pmol/mg albumin]) when compared toand 5-GCAATGGTTCAAGCGATTCTT-3 (reverse
primer). After electrophoresis size separation, the PCR the GA and AA groups combined (21.4 Mol/L [range,
7.6 to 384 pmol/mg albumin; P  0.05]). Additionally,product was confirmed by ultraviolet (UV) transillumi-
nation of gels stained by EtBr (1.5% agarose). The pyro- patients with the GG genotype presented a higher preva-
lence of positive serology for C. pneumoniae (51%) whensequencing reaction was performed on a PSQ96 Instru-
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Table 1. Main characteristics of the study population divided into genotypes
Genotype groups
GG GA and AA P value
Patients N 112 43
Age years 511 516 NS
Males % 64 51 NS
GFR mL/min 70.2 6.50.4 NS
CVD % 35 16 0.05
Malnutrition % 33 31 NS
Diabetes % 27 21 NS
IL-6 pg/mL 5.9 (range, 0.9–26) 5.9 (range, 1.3–45) NS
Pentosidine pmol/mg albumin 28.4 (range, 8.5–123) 21.4 (range, 7.6–384) 0.05
Chlamydia pneumoniae seropositivity % 51 24 0.05
high prevalence of both traditional risk factors, such as
hypertension and diabetes mellitus, and nontraditional
risk factors, such as inflammation and oxidative stress
[5]. MPO is released by activated polymorphonuclear
neutrophils as part of the defense system of the organism,
resulting in production of hypochlorous acid, a potent
oxidant [6]. In light of the links between oxidative stress,
inflammation, and CVD, we hypothesize that factors af-
fecting the expression of MPO may be involved in the
development of atherosclerosis. In this investigation, we
provide unique evidence indicating that a highly func-
tional genetic variation in the MPO gene (463G→AFig. 1. Associations between the MPO genotypes and cardiovascular
disease. Dots represent the regression coefficient and the lines represent SNP) is associated with the decreased presence of cardio-
the 95% confidence interval. Traditional risk factors included in the vascular disease in ESRD.
multivariate regression model were age, diabetes mellitus, and smoking,
Several studies have previously applied the same ap-and nontraditional risk factors included inflammation (plasma IL-6)
and malnutrition (SGA 2). proach to investigate associations between the463G→A
SNP and other disease states. Indeed, the frequency of
the G allele was also associated with a higher risk of Alz-compared to the carriers of the A allele (24%) (P 
heimer’s disease [7], lung cancer [8], and coronary artery0.05). The prevalence of CVD as defined by medical
disease in non-uremic individuals [9]. In the presenthistory was also significantly higher in the GG group
study, we report a very similar genotype distribution ofwhen compared to GA and AA groups combined. In
the variants in the MPO gene compared to the descrip-the univariate analysis performed as a first step of the
tion in other population groups [7, 9, 10]. These findingslogistic regression model, the GG genotype was signifi-
suggest that the SNP analyzed does not vary significantlycantly associated with CVD (chi-square 4.8; regression
among different populations around the world. We be-coefficient 0.36, CI 0.14% to 0.89%; P  0.05). The tra-
lieve that our findings have at least two major implica-ditional risk factors age, diabetes mellitus and smoking,
and also the nontraditional risk factors, IL-6 and malnu- tions: a) they facilitate the identification of biologic path-
trition, were significantly associated with CVD in the ways involved in atherosclerosis; and b) the use of the
univariate model. In contrast, male gender, serum cho- 463G→A SNP in the risk stratification for CVD in
lesterol, and blood pressure parameters were not signifi- ESRD.
cantly associated with CVD, and therefore were excluded Atherosclerosis is a chronic inflammatory process in
from the multivariate step of the regression model. After which oxidative damage within the artery wall is impli-
adjustment for age, diabetes mellitus, smoking, malnutri- cated in the pathogenesis of the disease. Although most
tion, and inflammation, the GG genotype remained sig- of the data concerning atherosclerosis as an inflamma-
nificantly associated with the CVD (chi-square 4.1, re- tory disease comes from animal models, evidence from
gression coefficient 0.12, CI 0.01% to 0.92%; P  0.05) a recent clinical study in non-renal patients shows that
(Fig. 1). widespread inflammation (increased MPO in neutro-
phils) is present regardless of the location of stenotic
DISCUSSION sites [11]. There is growing evidence of the important
role of MPO in the pathogenesis of atherosclerosis, start-The prevalence of atherosclerotic CVD is extremely
high in patients with ESRD, probably as a result of a ing from identification of the enzyme in the atheroscle-
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rotic plaques, where it was catalytically active and re- in the present study. This might reflect the fact that in-
flammatory markers are quite variable and influencedsponsible for the oxidation of low-density lipoprotein
(LDL) [12]. In fact, multiple distinct products of MPO, mostly by nongenetic factors, such as age, residual renal
function, gender, comorbidities, and intermittent clinicalsuch as 3-chlorotyrosine, are enriched in human athero-
sclerotic lesions and LDL recovered from human ather- events, including infections.
The chief finding of the present study is the associationoma [13]. Moreover, in a recent study, MPO was linked
to the modulation of the vascular signaling and vasodila- between the MPO genetic variation and the presence of
CVD based on medical history in incident predialysistory functions of nitric oxide (NO) during acute inflam-
mation, impairing the endothelium-dependent relaxant patients, confirming results previously described by Nik-
poor et al [9] in a group of non-uremic patients withresponse through the catalytic consumption of NO by the
free radicals generated by MPO [14]. Therefore, MPO coronary artery disease. In line with these findings, a
study by Kutter et al [19] demonstrated that patientsactivity may be implicated in the development of cardio-
vascular disease through at least two distinct pathways: 1) with inherited MPO deficiency presented a protection
increased oxidative stress in the atherosclerotic plaques; against CVD. It should be emphasized that despite the
and 2) interference in the endothelium relaxant re- relatively low number of patients included in our study,
sponse. Unfortunately, in the present study we did not the predictive value of the MPO genetic variation evalu-
measure MPO activity or the mRNA expression, and the ated appeared to be quite strong, holding its significance
indirect evidence that the genotype affects the enzyme even after adjustment for several comorbidities.
function is extrapolated from previous in vitro models. In summary, we found that the presence of the A allele
This potential limitation does not allow us to rule out (463G→A SNP) is associated with lower prevalence of
that the 463 G→A SNP is in linkage disequilibrium CVD in predialysis ESRD patients. Furthermore, the
with other SNPs in the MPO gene, and that those SNPs prevalence of C. pneumoniae seropositivity was lower in
could be affecting the transcriptional or translational the GA and AA groups, and plasma pentosidine concen-
status, or the enzyme activity itself, instead of the herein tration was lower in the carriers of the A allele, which
investigated SNP. may be a consequence of a reduced production of free
Himmelfarb et al [15] recently showed that the forma- radicals resulting from lower MPO activity in this group
tion of MPO-catalyzed 3-chlorotyrosine is increased also of patients. Our data provide epidemiologic support for
in dialysis patients and related to oxidative stress. Al- the hypothesis that increased oxidative stress related to
though several putative markers of oxidative stress have MPO activity is associated with atherosclerotic CVD in
been used previously, there is no established golden stan- ESRD patients.
dard. In this study, we used pentosidine as an indirect
marker of oxidative protein damage, since pentosidine ACKNOWLEDGMENTS
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